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Faecal calprotectin (FCP) is a powerful tool to predict inflammatory bowel disease (IBD) in
patients with gastrointestinal symptoms. In the paediatric patient population, the reference
value of < 50 μg/g and the influence of age on FCP levels result in a high number of redun-
dant investigations and specialist referrals. We assessed paediatric FCP levels, their diag-
nostic value and corresponding referral pathways from primary and secondary care.
Methods
We analysed two cohorts from a precisely defined catchment area: one consisted of all
FCPs measured in this area (n = 2788). The second cohort—a subset of the first cohort—
consisted of FCP values and corresponding clinical data from children who were referred for
possible IBD to our department (n = 373).
Results
In the first cohort, 47% of FCP levels were > 50 μg/g, 15% were� 250 μg/g. Children < 1y
had significantly (p < 0.001) higher FCP than older children. In the second cohort, 6.7% of
children with an FCP of < 250 μg/g (or 8.6% with an FCP of < 600 μg/g) had IBD–all featured
symptoms suggestive of IBD (e.g. bloody diarrhoea, nocturnal abdominal pain, weight loss)
or abnormal blood tests. 76% of patients in whom raised FCP (> 50 μg/g) was the sole rea-
son for being referred for suspected IBD did not have IBD.
Conclusion
Children with an FCP < 600 μg/g and without matching symptoms suggestive of IBD are
unlikely to have IBD. A higher FCP reference value may provide cost-effective improvement
that could avoid redundant investigations and specialist referrals. A guideline for specialist
referrals is proposed.
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Introduction
Detection of the faecal calprotectin (FCP) has been established as a highly reliable, yet non-spe-
cific marker for gastrointestinal (GI) inflammation [1–3]. The clinical application of FCP cur-
rently covers mainly two areas; (i) as a screening tool in the diagnostic work up for
inflammatory bowel disease (IBD) in patients with GI symptoms [2, 4, 5] and (ii) to monitor
disease activity in patients with IBD [6–9]. A reliable and valid reference value is critical for a
screening test, but many laboratories still do not provide age-appropriate reference ranges.
This is despite the well-documented higher FCP levels in healthy young children, especially in
children aged< 6 years [10–15]. This inevitably leads to unnecessary healthcare costs,
let alone potentially invasive investigations for children [16, 17].
Furthermore, an increasing number of children suffer from unspecific GI symptoms such
as abdominal pain or diarrhoea. The most accurate way to assess these children for possible
IBD is the right interpretation of the combination of matching symptoms suggestive of IBD,
blood test results and FCP values above 250 μg/g [18, 19]. However, as we have seen now in
our cohort, many doctors in primary care (General Practitioners, GPs) and secondary care
(General Paediatricians) in the United Kingdom refer children to the paediatric gastroenterol-
ogist for possible IBD with a slightly elevated FCP just above 50 μg/g, regardless of matching
symptoms suggestive of IBD and/or abnormal blood tests.
Studies assessing the wide use of FCP in primary and secondary care are scarce. This is
despite the fact that GPs and General Paediatricians are the first port of call for children and
refer a child to the paediatric gastroenterologist. As pressure on costs in health care rises, accu-
racy and standardisation of diagnostic testing and the correct interpretation of a test result are
highly needed. The aims of this study are (1) to assess age-appropriate FCP values in children,
(2) to assess thresholds of FCP used by primary and secondary care to refer children for sus-
pected IBD to a tertiary level gastroenterology department and (3) to develop a practical guide-
line for the differentiated interpretation of FCP and for referrals from primary and secondary
care.
Methods
Patient cohort and study design
We used the Cambridge University Hospitals (CUH) electronic patient record system “Epic”
to compile FCP values and clinical data. “Epic” contains all FCP values that were ordered from
all hospitals, general paediatricians and general practitioners of a specific, clearly defined
catchment area around Cambridge. The catchment areas in the UK health system steadily
cover strictly specific towns and their related hospitals, general paediatricians and GPs. There-
fore, all FCP values ordered in this catchment area were analysed at the CUH biochemistry
laboratory. Moreover, all children of this catchment area would be referred to our tertiary pae-
diatric gastroenterology unit.
We analysed two cohorts of FCP values: one cohort consisted of all FCP levels analysed
between October 2014 and July 2018 from children aged 0–16 years, resulting in a total of
2788 FCP values performed on 2788 children (1676 female, 1112 male, Table 1).
This cohort comprises FCP results that were ordered and interpreted by GPs and Paediatri-
cians in the defined catchment area—the majority of these patients were not referred nor
assessed at our paediatric gastroenterology department. The second cohort—being a subset of
the first cohort—consisted of FCP values from children who were referred from the same catch-
ment area to our paediatric gastroenterology department by GPs or Paediatricians. Referrals
were sent for possible IBD due to an elevated FCP level above 50 μg/g—with or without
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matching symptoms suggestive of IBD. For this analysis, we included FCP results of all referred
children with complete data entries on “Epic” (including recorded referral letter and clinical
characteristics like age, sex, gastrointestinal symptoms, final diagnosis, blood test results and
medication such as non-steroidal anti-inflammatory drugs NSAIDs). We excluded FCP values
without corresponding or complete data entry on “Epic”, FCP requested by our paediatric
gastroenterology department and FCP of children with IBD diagnosed prior to October 2014.
Each referral letter was screened and the following information was obtained: by whom
(GP/paediatrician/paediatric gastroenterologist) the child had been referred, blood test results
previous to the referral and whether the referral was done solely because of the raised FCP
(> 50 μg/g, regardless of matching symptoms suggestive of IBD) or because of GI symptoms
(along with a raised FCP). We identified 373 FCP firstly measured values from 373 children
who met the inclusion criteria. Thereof, 96 patients were subsequently diagnosed with IBD.
All children with confirmed IBD received a diagnostic endoscopy (oesophagogastroduodeno-
scopy and ileocolonoscopy with biopsies) at our department to confirm a diagnosis of IBD
based on the Porto criteria for diagnosing IBD in children [18].
All children with suspected IBD in our above mentioned catchment area would be referred
to our paediatric gastroenterology department hence a diagnosis of IBD would only be con-
firmed at our institution (CUH) upon endoscopic, histological and imaging findings.
In some of the analyses we used age groups (< 1y, 1-5y, 6-14y, 15-16y) to enable the com-
parison of our results with previous findings [10, 12].
Despite the fact that many children had multiple FCP results, we used only the first mea-
surement per child for statistical reasons.
FCP assay
FCP levels were measured at CUH biochemistry laboratory using a standardised ELISA (Bühl-
mann fCal, Schönenbuch, Switzerland). Results were provided in μg/g with< 50 μg/g as nor-
mal reference value which was defined by the test kit provider Bühlmann at the time of the
study. The maximum value for this test kit in our laboratory was reported as “> 600 μg/g”.
Data analyses
Statistical analyses were performed in R version 3.5.0 [20]. A two-sided T-test was applied for
quantitative variables and a Chi-Square-test and Welch two sample adaptation for categorical
Table 1. Summary table of faecal calprotectin (FCP) measurements at Cambridge University Hospitals between
October 2014 to July 2018.
Description Number
Total FCP values measured 45‘717
Total FCP values measured in children 0-16y (incl. multiples) measurements) 3‘461
thereof repeat measurements on same patient 673
Single FCP measurements of children 0–16 y 2‘788
thereof female children 1‘676
thereof male children 1‘112
FCP values with corresponding entry on „EPIC”(= referred children) 377
Children with new diagnosis of IBD 96
Children referred by General Practitioners 216
Children referred by General Paediatricians 157
Children referred by Paediatric Gastroenterologists 4
https://doi.org/10.1371/journal.pone.0246091.t001
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variables. Data is presented as absolute numbers, percentages, box and whisker plots with
median and mean. We used median rather than mean values to calculate significance because
means are more influenced by outliers and our laboratory reports very high values only as “>
600 μg/g”.
For the analysis of the receiver operating curve (ROC) and the area under the curve (AUC)
we used the pROC package. To produce the ROC we fitted a logistic regression model and
computed the AUC. The optimal cut-off value for FCP for diagnosing IBD was suggested by
the “coords” function in the pROC package.
We analysed three different FCP cut-off levels: 50 μg/g as it is the current normal reference
level; 250 μg/g as FCP levels of> 250 μg/g have been suggested as cut-off values to predict
mucosal inflammation in IBD according to the European Society of Paediatric Gastroenterol-
ogy, Hepatology and Nutrition (ESPGHAN) [9], and 600 μg/g as our laboratory reports very
high values only as “> 600 μg/g”.
Ethics statement
All data and samples of faecal Calprotectin used in this study were fully anonymized before we
accessed them. Data contained hospital and patient identification numbers, date of birth, gen-
der, date of sampling and value of faecal Calprotectin, name of the corresponding General
Practitioner and whether a prescription for non-steroidal anti-inflammatory drugs (NSAIDs)
was present or not. Data from the time frame October 2014—July 2018 were accessed through
the Cambridge University Hospital’s electronic patient record system “Epic”. This study was
registered as an audit with the Cambridge University Hospitals Audit Department (project
number 26763956), and it was approved by the Research Ethics Committee (REC) of the Cam-
bridge University Hospitals NHS Foundation Trust.
Results
Almost half of all paediatric FCP levels exceed current normal reference
levels
In our first cohort (n = 2788), where all FCP levels of children from our catchment area were
included, we investigated FCP levels regardless of the underlying diagnosis to overview the
FCP distribution of our cohort (Fig 1A). As shown in Fig 1B, 47% exceed the current normal
reference level of 50 μg/g. 10% (n = 278) of FCP lied� 600 μg/g, resulting in 85% of samples
below 250 μg/g.
FCP levels are higher in children under the age of 1 year
To investigate whether young children (age < 6y) have higher FCP values than older children,
we compared the FCP levels of different age groups in the first cohort (n = 2788). The average
FCP level was found to be significantly (p< 0.001) higher in infants (aged < 1y) compared to
all other age groups (Table 2).
Similarly, the median FCP in the age group 1-5y was significantly higher (p< 0.001) when
compared to the 6-14y old group. However, the clinical FCP value was similar (41 vs. 47 μg/g).
The difference in the median FCP between the age group 6-14y and 15-16y as well as between
1-5y and 15-16y was not statistically significant (p = 0.080 and 0.099, respectively, Table 2).
Increasing FCP reference range improves diagnostic accuracy for IBD
Based on findings so far, we hypothesised that applying a threshold for FCP higher than 50 μg/
g in children may increase the accuracy for diagnosing IBD. For these analyses, we used the
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second cohort (n = 373), which consists of all children referred by doctors from our precisely
defined catchment area for possible IBD. None of these children were taking NSAIDs nor had
a gastrointestinal polyp nor a gastrointestinal infection that could have increased the FCP. As
we know the exact clinical data and the final diagnosis of the whole cohort, we could then iden-
tify all children with a confirmed diagnosis of IBD. Of the 373 patients who met the inclusion
criteria, 96 had been diagnosed with IBD by upper and lower endoscopy and biopsies accord-
ing to the Porto criteria for diagnosing IBD in children [18]. As shown in Fig 2A, 96% of chil-
dren with an FCP level of< 250 μg/g were not diagnosed with IBD. In contrast, almost 46% of
patients with FCP levels > 250 μg/g were ultimately diagnosed with IBD, with the percentage
increasing to 60% in children with FCP levels > 600 μg/g (Fig 2A).
Table 3 shows that seven children with IBD (6.7% of all children with IBD) had an FCP
of< 250 μg/g (i.e. 92, 101, 190, 211, 232 and 245 μg/g) and two children with IBD (1.9%) had
an FCP of 250–599 μg/g (i.e. 313 and 529 μg/g).
Importantly, all of these patients with an FCP < 600 μg/g and IBD presented initially with
matching symptoms suggestive of IBD (i.e. bloody diarrhoea, weight loss, nocturnal abdomi-
nal pain) and/or at least one abnormal blood tests (i.e. elevated C-reactive protein and/or
erythrocyte sedimentation rate, anaemia, raised platelets, low albumin, raised liver/bile
Fig 1. Distribution of faecal calprotectin (FCP) in the total cohort, including samples of healthy children and children with a
gastrointestinal condition (e.g. IBD). A Scatterplot of absolute FCP distribution of 2788 samples from 2788 children aged 0-16y. B
Percentage of all patients (n = 2788) according to FCP range. 85% of all FCP values are< 250 μg/g, 90% are< 600 μg/g.
https://doi.org/10.1371/journal.pone.0246091.g001
Table 2. Summary of age-group-related comparison in FCP levels of the first cohort (n = 2788).
Age group Number of patients Median FCP (μg/g) Interquartile range p value
< 1y n = 34 205 498 p < 0.001 compared to all other age groups
1-5y n = 582 55 120 p < 0.001 compared to 6-14y
6-14y n = 1598 41 80 p = 0.080 compared to 15-16y
15-16y n = 579 47 113 p = 0.099 compared to 1-5y
FCP: Faecal Calprotectin.
https://doi.org/10.1371/journal.pone.0246091.t002
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enzymes) (Table 3). Four children with IBD (= 4% of all children with IBD) were at the age
of< 6y at the diagnosis. They all showed matching symptoms suggestive of IBD (Table 3).
The ROC analysis revealed an AUC of 86.11%. The optimal FCP cut-off value was 600 μg/g.
The true positive percentage (tpp)/sensitivity at this threshold was 91.58% and the false posi-
tive percentage (fpp)/(1-specificity) was 21.80%. The tpp and fpp at FCP 50 μg/g cut-off are
100% and 93.98%, and those at FCP 250 μg/g cut-off were 93.68% and 39.10%, respectively. A
Fig 2. A Proportion of patients with newly diagnosed IBD (red) and without IBD (green) according to their FCP of</� 50 μg/g,</� 250 μg/g and
</� 600 μg/g. The difference between IBD diagnoses in patients with FCP< and� 250 μg/g as well as in those with FCP< and� 600 μg/g is
statistically significant (p< 0.05). B Proportion of patients with/without IBD who were referred due to and not due to their elevated FCP (Ref. FCP and
Ref. not FCP, respectively). C Proportion of patients with/without IBD and referred due to their FCP of 50–250 μg/g.
https://doi.org/10.1371/journal.pone.0246091.g002
Table 3. Summary of symptoms and blood test results of IBD patients with FCP< 600 μg/g (n = 9) and of IBD
patients aged < 6y (n = 4).
Description of IBD
patient
Symptoms Blood test results
Patient 1, FCP < 250 μg/g PR bleeding, nocturnal abdominal pain, watery
diarrhoea
Anaemia
Patient 2, FCP < 250 μg/g PR bleeding, watery diarrhoea Anaemia
Patient 3, FCP < 250 μg/g Diarrhoea, vomiting, nocturnal abdominal pain Anaemia, raised CRP/ESR, low
Albumin
Patient 4, FCP < 250 μg/g PR bleeding, abdominal pain Raised ESR
Patient 5, FCP < 250 μg/g PR bleeding, abdominal pain Raised ESR and platelets
Patient 6, FCP < 250 μg/g PR bleeding, weight loss Normal bloods
Patient 7, FCP < 250 μg/g PR bleeding Normal bloods
Patient 8, FCP 250–
599 μg/g
Watery diarrhoea Anaemia, low Albumin
Patient 9, FCP 250–
599 μg/g
Weight loss, PR bleeding, abdominal pain Raised CRP, ESR and liver enzymes
Patient 10, age < 6y Weight loss, abdominal pain, vomiting Anaemia, raised CRP
Patient 11, age < 6y PR bleeding Anaemia
Patient 12, age < 6y PR bleeding Raised CRP/ESR
Patient 13, age < 6y Watery diarrhoea, weight loss Anaemia, low Albumin
IBD inflammatory bowel disease; FCP faecal calprotectin; PR per rectum; CRP C-reactive protein; ESR erythrocyte
sedimentation rate.
https://doi.org/10.1371/journal.pone.0246091.t003
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split of the data into different age groups revealed similar AUCs (no significant differences)
and therefore supports the same thresholds.
Specialist referrals are frequently based on FCP levels
Many referrals received by GPs and Paediatricians were exclusively based on (slightly) elevated
FCP just above 50 μg/g and irrespective of the presence of matching symptoms suggestive of
IBD. This means, that the child may have had abdominal pain, diarrhoea or nausea that led to
an FCP measurement, in the absence of red flag signs like nocturnal abdominal pain, bloody
diarrhoea or vomiting. We therefore assessed the referral pathways, the subsequent diagnosis
of IBD and the reliability of FCP in the diagnosis of IBD.
In the observed study period, 373 of the 2788 children who had an FCP performed were
referred for possible IBD to our paediatric gastroenterology department; 216 (58%) by GPs,
157 (42%) by General Paediatricians (Table 1). Of 373 referrals from GPs or Paediatricians,
167 (45%) were made solely because of an elevated FCP> 50 μg/g irrespective of matching
symptoms suggestive of IBD (so called “red flags symptoms”, i.e. nocturnal abdominal pain,
bloody diarrhoea, vomiting, weight loss) whilst 206 (55%) were made for matching symptoms
suggestive of IBD and/or abnormal blood tests in addition to an elevated FCP.
Fig 2B shows the quantity of patients who were referred for possible IBD only due to their
raised FCP versus those who were referred solely because of their symptoms alongside a raised
FCP. We then investigated how many of them had been diagnosed with IBD afterwards. All
patients included in this analysis had an FCP done prior to the referral.
Overall, 24% of all children referred due to their elevated FCP were diagnosed with IBD.
29% of the children whose primary reason for referral was not their elevated FCP were also
subsequently diagnosed with IBD.
Children with an FCP of 50–250 μg/g and who were referred solely because of their raised
FCP, only four patients (5.5%) were diagnosed with IBD (Fig 2C). Their FCP level was 92, 101,
232 and 245 μg/g.
Implications for paediatric practice
Our findings show that only a small percentage of patients (15%) have an FCP of> 250 μg/g
and thereof, IBD is unlikely in a patient without matching clinical symptoms or abnormal
blood test, as already shown by Van de Vijver et al. [17]. In order to support doctors in primary
and secondary care in the decision making of whether FCP should be tested and a patient
needs to be seen by a specialist, we suggest a flowchart as a clinical guidance (Fig 3). This flow-
chart is based on the findings of this study, the recommended increase of FCP cut-off to
250 μg/g by the ESPGHAN guidelines [9] and our clinical experience.
This guideline aims to reduce unnecessary investigations like endoscopies and repeated
FCP measurements and to avoid redundant specialist referrals. If a child presents with match-
ing symptoms suggestive of IBD (so-called “red flag” symptoms) and has additionally one or
more abnormal blood tests (anaemia, raised platelets/CRP/ESR/liver enzymes, low albumin),
the priority should be to have the child referred promptly to a paediatric gastroenterologist,
who will use the FCP result to make a decision about specialist investigations. If a child only
has abnormal blood test results in the absence of “red flag” symptoms, FCP should be tested
and in case of a level < 250 μg/g in two separate samples, IBD will be unlikely and no further
investigations should be performed. Based on clinical practice we recommend to test FCP
twice in primary and secondary care, however for the purposes of the statistical analysis we
used one measurement per patient. We hope this guideline will facilitate the decision making
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on how to proceed with a child presenting with gastrointestinal symptoms in primary and sec-
ondary care.
Discussion
We assessed the results of FCP samples from two large paediatric cohorts referred to a regional
paediatric gastroenterology unit, assuming that all subsequent cases of IBD were then diag-
nosed in this unit. Overall, 47% of all FCP values lay> 50 μg/g and 85% lay< 250 μg/g, regard-
less of the underlying diagnosis. Assuming that far less than 50% of patients who undergo FCP
testing will ultimately be diagnosed with a GI disease such as IBD, these data clearly highlight
that the current normal reference value of 50 μg/g is not an accurate threshold in the paediatric
population.
In our study, the mean FCP is significantly higher in infants (aged < 1y) when compared to
older children. This finding is based only on few patients (n = 34), but still it provides further
evidence that infants have higher FCP levels than children aged> 1y. Previous studies
reported higher FCP levels mainly in children under the age of 6y [10–15]. In our study, the
difference in the FCP level between the age groups 1-5y compared to 6-14y, was—although sta-
tistically significant—not clinically relevant (41 vs. 47 μg/g).
Previous studies have provided inconsistent recommendations for age-related reference
values in children, along with a variable diagnostic accuracy for diagnosing IBD in children [1,
2, 21–26]. Additionally, there are promising results from prospective studies with newer tests
like Calgranulin C for the diagnostic workup of IBD [24, 25]. Whilst our retrospective data
analysis cannot provide an accurate new reference range for FCP in each age group, it provides
further evidence that a general increase of the FCP cut-off to at least 250 μg/g in children aged
0-16y appears appropriate [9, 18, 26]. This is due to the fact that (i) 85% of all FCP values
lay< 250 μg/g (including healthy children and children with an underlying GI condition) and
(ii) only 7 children with IBD (= 6.7% of children with IBD) had an FCP of< 250 μg/g and they
all showed at least one matching symptom suggestive of IBD and/or abnormal blood tests.
Fig 3. Flowchart providing a guideline on how to proceed with a child presenting with gastrointestinal symptoms
in primary and secondary care. IBD Inflammatory bowel disease; PR per rectum; TTG Tissue Transglutaminase; GI
gastrointestinal; CRP C-reactive protein; ESR erythrocyte sedimentation rate; LFT’s liver function tests; GP General
Practitioner.
https://doi.org/10.1371/journal.pone.0246091.g003
PLOS ONE Interpretation of faecal calprotectin levels in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0246091 February 11, 2021 8 / 11
In the group referred to us for possible IBD solely because of an elevated FCP just above
50 μg/g, 24% had been diagnosed with IBD subsequently. The low occurrence of IBD is even
more evident in the subgroup with an FCP of 50–250 μg/g who were referred solely because of
their FCP level: only four patients (2.8%) had IBD. This is most obviously explained by the fact
that an elevated FCP alone is a weaker indicator of IBD than appropriate symptoms accompa-
nied by an elevated FCP [18]—especially in primary and secondary care, where the prevalence
of IBD is low.
Only nine out of ninety-six patients with IBD (= 8.6% of all children with IBD) had a FCP
of < 600 μg/g at diagnosis, with five patients (56%) being referred due to their symptoms
and/or blood test results, and not because of their FCP level. All nine patients showed match-
ing symptoms suggestive of IBD (red flag symptoms) or abnormal blood test results. We
found that if the FCP in a child—seen at this point by a paediatric gastroenterologist—
is < 600 μg/g, IBD is unlikely in the absence of matching symptoms suggestive of IBD or in
the absence of abnormal blood tests. This message is supported by the ROC/AUC analysis for
the IBD probability, as it revealed a corresponding FCP cut-off value of 600 μg/g. This was
expected as most of our patients with IBD had FCP� 600 μg/g. In view of these findings, a
more useful advisory for paediatric gastroenterologists recommending a diagnostic endos-
copy in children would be an FCP of > 600 μg/g in the presence of appropriate symptoms
and/or abnormal blood tests.
Conclusion
Our findings further support the recommendation that FCP levels of 250 μg/g or more are
required in children with GI symptoms suggestive of IBD to refer to a paediatric gastroenterol-
ogist. Further prospective studies are needed to validate this statement. For the paediatric gas-
troenterologists, we advise to be aware that an FCP result below 600 μg/g makes a diagnosis of
IBD less likely, even in presence of symptoms. In addition, GPs and General Paediatricians
should remain alert to the frequent high levels of FCP in children aged< 6y. Therefore, a flow-
chart for guidance on how to proceed with a child with gastrointestinal symptoms in primary
and secondary care is provided. We take the view that there is an urgent need for an ESP-
GHAN guideline on the use of faecal Calprotectin.
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